Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANVS 
Annovis Bio Inc (ANVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: ANVS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14.25
1 Year Target Price $14.25
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -86.46% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.39M USD | Price to earnings Ratio - | 1Y Target Price 14.25 |
Price to earnings Ratio - | 1Y Target Price 14.25 | ||
Volume (30-day avg) 4 | Beta 1.62 | 52 Weeks Range 1.11 - 11.69 | Updated Date 07/16/2025 |
52 Weeks Range 1.11 - 11.69 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -91.05% | Return on Equity (TTM) -280.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 31156097 | Price to Sales(TTM) - |
Enterprise Value 31156097 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.57 | Shares Outstanding 19486200 | Shares Floating 15624645 |
Shares Outstanding 19486200 | Shares Floating 15624645 | ||
Percent Insiders 14.69 | Percent Institutions 16.03 |
Upturn AI SWOT
Annovis Bio Inc
Company Overview
History and Background
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegenerative diseases. Founded in 2008, it focuses on developing therapies for Alzheimer's, Parkinson's, and other related disorders. It has evolved from early research to clinical trials.
Core Business Areas
- Drug Development: Development of therapeutics for neurodegenerative diseases, focusing on protein translation inhibitors to reduce toxic proteins.
Leadership and Structure
Maria L. Maccecchini is the President and CEO. The company has a board of directors and a management team focused on clinical development and research.
Top Products and Market Share
Key Offerings
- Buntanetap (ANVS401): Buntanetap is Annovis Bio's lead drug candidate, a translation inhibitor targeting multiple toxic proteins, including amyloid-beta, tau, and alpha-synuclein. Currently in clinical development for Alzheimer's and Parkinson's disease. Market share is currently negligible as it is not approved yet. Competitors include large pharmaceutical companies with marketed Alzheimer's and Parkinson's drugs.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing, with significant unmet medical needs, especially in Alzheimer's and Parkinson's. There is increasing investment in research and development.
Positioning
Annovis Bio is a smaller player focused on a novel approach of inhibiting protein translation. It aims to differentiate itself through its multi-target mechanism and potential to address multiple neurodegenerative diseases.
Total Addressable Market (TAM)
The global Alzheimer's disease market is expected to reach hundreds of billions of dollars. Annovis Bio is positioned to potentially capture a small but significant share if Buntanetap is approved.
Upturn SWOT Analysis
Strengths
- Novel multi-target mechanism
- Potential to address multiple neurodegenerative diseases
- Promising early clinical data
Weaknesses
- Limited financial resources
- High risk of clinical trial failure
- Reliance on a single drug candidate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- BIIB
- VTVT
Competitive Landscape
Annovis Bio faces intense competition from larger pharmaceutical companies with more resources and approved drugs. Its competitive advantage lies in its novel mechanism and multi-target approach, but it carries significant risk due to its reliance on a single drug candidate. ABBV and LLY have the largest market share, followed by BIIB.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on advancing Buntanetap through clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and potential partnerships. Analyst projections are speculative and highly dependent on clinical data.
Recent Initiatives: Recent initiatives include advancing Buntanetap in Phase 2 and 3 clinical trials for Alzheimer's and Parkinson's disease.
Summary
Annovis Bio is a high-risk, high-reward clinical-stage company focused on neurodegenerative diseases. Its Buntanetap drug candidate has a novel mechanism that targets multiple toxic proteins. The company faces significant competition and financial challenges but could see substantial gains if its clinical trials are successful. Investors should carefully consider the risks before investing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Annovis Bio Inc. website
- SEC filings (10-K, 10-Q)
- Analyst reports
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Annovis Bio Inc
Exchange NYSE | Headquaters Malvern, PA, United States | ||
IPO Launch date 2010-02-12 | Founder, CEO, President & Executive Director Dr. Maria L. Maccecchini Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.annovisbio.com |
Full time employees 8 | Website https://www.annovisbio.com | ||
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.